Back to results
US 2024/0391997 A1Published application
Anti-tim-3 antigen antibody or antibody derivative, and use thereof
AssigneeBrightPath Biotherapeutics Co., Ltd.
InventorsKanto Nakajima, Mamoru Shiraishi, Takahiko Aramaki, Haruka Matsumura, Noriko Matsumoto
Life of this patent
Estimating the term…
Abstract
An antibody or an antibody derivative with enhanced functionality targeting the Tim-3 antigen. The antibody binds to the Tim-3 antigen, has complementary determining regions in the heavy and light chains with specific amino acid sequences, and can activate T cells with cytotoxic effects against cancer cells.
Claims26
A heterodimeric antibody or antibody derivative that is a combination of two different half-molecules each of which binds to the Tim-3 antigen and enhances immune activity against cancer cells.
A homodimeric antibody or antibody derivative which binds to the Tim-3 antigen and enhances immune activity against cancer cells, comprising a set of the complementarity-determining regions of the heavy and light chains selected from the group consisting of:
- (1) complementarity-determining regions of the heavy chain, CDR1 (SYYMS, SEQ ID No:
- 1), CDR2 (TISNSGGSIYYLDSVKD, SEQ ID No:
- 2), and CDR3 (DPYYSNYVPMDY, SEQ ID No:
- 3), and
- complementarity-determining regions of the light chain, CDR1 (KASQYVDTYVA, SEQ ID No:
- 4), CDR2 (SASTRHT, SEQ ID No:
- 5), and CDR3 (AQYSSSPLT, SEQ ID No:
- 6);
- (2) complementarity-determining regions of the heavy chain, CDR1 (DYYMD, SEQ ID No:
- 9), CDR2 (YIYPNNGGTSYNQKFKG, SEQ ID No:
- 10), and CDR3 (SGYGNYYTMDY, SEQ ID No:
- 11), and
- complementarity-determining regions of the light chain, CDR1 (KASQSVGNNVA, SEQ ID No:
- 12), CDR2 (YASNRYT, SEQ ID No:
- 13), and CDR3 (QQHYSSPST, SEQ ID No:
- 14);
- (3) complementarity-determining regions of the heavy chain, CDR1 (DYYMD, SEQ ID No:
- 17), CDR2 (YIYPNNGGTSYNQKFKG, SEQ ID No:
- 18), and CDR3 (GGYYSYYSYDY, SEQ ID No:
- 19), and
- complementarity-determining regions of the light chain, CDR1 (KASQSVGNNVA, SEQ ID No:
- 20), CDR2 (YASNRYT, SEQ ID No:
- 21), and CDR3 (QQHYSSPYT, SEQ ID No:
- 22);
- (4) complementarity-determining regions of the heavy chain, CDR1 (DYYMD, SEQ ID No:
- 25), CDR2 (YIYPNNGGTSYNQKFKG, SEQ ID No:
- 26), and CDR3 (SGYKAYYAMDY, SEQ ID No:
- 27), and
- complementarity-determining regions of the light chain, CDR1 (KASQSVGNNVA, SEQ ID No:
- 28), CDR2 (YASNRYT, SEQ ID No:
- 29), and CDR3 (QQHYSSPYT, SEQ ID No:
- 30);
- (5) complementarity-determining regions of the heavy chain, CDR1 (SYYMS, SEQ ID No:
- 33), CDR2 (TISNSGGSTYYPDSVKD, SEQ ID No:
- 34), and CDR3 (DPYYTNYVPMDY, SEQ ID No:
- 35), and
- complementarity-determining regions of the light chain, CDR1 (KASQYVDTYVA, SEQ ID No:
- 4), CDR2 (SASTRHT, SEQ ID No:
- 5), and CDR3 (AQYSSSPLT, SEQ ID No:
- 6);
- (6) complementarity-determining regions of the heavy chain, CDR1 (SYYMS, SEQ ID No:
- 33), CDR2 (TISNSGGSTYYPDSVKD, SEQ ID No:
- 34), and CDR3 (DPYYTNYVPMDY, SEQ ID No:
- 35), and
- complementarity-determining regions of the light chain, CDR1 (KASENVGTYVS, SEQ ID No:
- 52), CDR2 (GASNRYT, SEQ ID No:
- 53), and CDR3 (GQSYSYPLT, SEQ ID No:
- 54);
- (7) complementarity-determining regions of the heavy chain, CDR1 (DYYMD, SEQ ID No:
- 9), CDR2 (YIYPNNAGTS YNQKFKG, SEQ ID No:
- 74), and CDR3 (SGYGNYYTMDY, SEQ ID No:
- 11), and
- complementarity-determining regions of the light chain, CDR1 (KASQSVGNNVA, SEQ ID No:
- 12), CDR2 (YASNRYT, SEQ ID No:
- 13), and CDR3 (QQHYSSPST, SEQ ID No:
- 14);
- (8) complementarity-determining regions of the heavy chain, CDR1 (DYYMD, SEQ ID No:
- 9), CDR2 (YIYPNKGGTS YNQKFKG, SEQ ID No:
- 76), and CDR3 (SGYGNYYTMDY, SEQ ID No:
- 11), and
- complementarity-determining regions of the light chain, CDR1 (KASQSVGNNVA, SEQ ID No:
- 12), CDR2 (YASNRYT, SEQ ID No:
- 13), and CDR3 (QQHYSSPST, SEQ ID No:
- 14);
- (9) complementarity-determining regions of the heavy chain, CDR1 (DYYMD, SEQ ID No:
- 17), CDR2 (YIYPNNAGTS YNQKFKG, SEQ ID No:
- 78), and CDR3 (GGYYSYYSYDY, SEQ ID No:
- 19), and
- complementarity-determining regions of the light chain, CDR1 (KASQSVGNNVA, SEQ ID No:
- 20), CDR2 (YASNRYT, SEQ ID No:
- 21), and CDR3 (QQHYSSPYT, SEQ ID No:
- 22);
- (10) complementarity-determining regions of the heavy chain, CDR1 (DYYMD, SEQ ID No:
- 17), CDR2 (YIYPNKGGTS YNQKFKG, SEQ ID No:
- 80), and CDR3 (GGYYSYYSYDY, SEQ ID No:
- 19), and
- complementarity-determining regions of the light chain, CDR1 (KASQSVGNNVA, SEQ ID No:
- 20), CDR2 (YASNRYT, SEQ ID No:
- 21), and CDR3 (QQHYSSPYT, SEQ ID No:
- 22);
- (11) complementarity-determining regions of the heavy chain, CDR1 (DYYMD, SEQ ID No:
- 25), CDR2 (YIYPNNAGTS YNQKFKG, SEQ ID No:
- 82), and CDR3 (SGYKAYYAMDY, SEQ ID No:
- 27), and
- complementarity-determining regions of the light chain, CDR1 (KASQSVGNNVA, SEQ ID No:
- 28), CDR2 (YASNRYT, SEQ ID No:
- 29), and CDR3 (QQHYSSPYT, SEQ ID No:
- 30);
- (12) complementarity-determining regions of the heavy chain, CDR1 (DYYMD, SEQ ID No:
- 25), CDR2 (YIYPNKGGTS YNQKFKG, SEQ ID No:
- 84), and CDR3 (SGYKAYYAMDY, SEQ ID No:
- 27), and
- complementarity-determining regions of the light chain, CDR1 (KASQSVGNNVA, SEQ ID No:
- 28), CDR2 (YASNRYT, SEQ ID No:
- 29), and CDR3 (QQHYSSPYT, SEQ ID No:
- 30).
93 more elements
Dependencies are inferred from the claim text.